Similar to NF1 patients with CHD and intragenic mutations, a significantly higher prevalence of non-truncating mutations was observed in patients with PVS (13/20, 65.0%) compared to patients without PVS (98/459, 21.4%) (p = 0.00185) (Figure 1c). This evidence concerns the gene NF1 and perivascular space measurement.